Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer

Oncogene

Volumn 29, Issue 10, 2010, Pages 1421-1430

  Kim, Y H ^a   Kwei, K A ^a   Girard, L ^b   Salari, K ^a,c   Kao, J ^a   Pacyna Gengelbach, M ^d   Wang, P ^e   Hernandez Boussard, T ^c   Gazdar, A F ^b   Petersen, I ^f   Minna, J D ^b   Pollack, J R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Fred Hutchinson Cancer Research Center   (United States)

^f JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Adapter protein; CRKL; DNA amplification; Genomic profiling; Lung cancer

Indexed keywords

BCR ABL PROTEIN; CRK LIKE PROTEIN; GROWTH FACTOR; RNA;

AMPLICON; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 22Q; CHRONIC MYELOID LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE LOCUS; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMES, HUMAN, PAIR 22; COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA INTERFERENCE;

EID: 77949424529     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.437     Document Type: Article

References (33)

1. Bashyam MD, Bair R, Kim YH, Wang P, Hernandez-Boussard T, Karikari CA et al. (2005). Array-based comparative genomic hybridization identifies localized DNA amplifications and homo-zygous deletions in pancreatic cancer. Neoplasia 7: 556-562.
2. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE et al. (2006). Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45: 1033-1040.
3. Daly RJ, Binder MD, Sutherland RL. (1994). Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene 9: 2723-2727.
4. Daly RJ, Gu H, Parmar J, Malaney S, Lyons RJ, Kairouz R et al. (2002). The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. Oncogene 21: 5175-5181.
5. de Jong R, ten Hoeve J, Heisterkamp N, Groffen J. (1997). Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site. Oncogene 14: 507-513.
6. Feller SM. (2001). Crk family adaptors-signalling complex formation and biological roles. Oncogene 20: 6348-6371.
7. Furge KA, Zhang YW, Vande Woude GF. (2000). Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 19: 5582-5589.
8. Garnis C, Lockwood WW, Vucic E, Ge Y, Girard L, Minna JD et al. (2006). High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 118: 1556-1564.
9. Gay B, Suarez S, Caravatti G, Furet P, Meyer T, Schoepfer J. (1999). Selective GRB2 SH2 inhibitors as anti-ras therapy. Int J Cancer 83: 235-241.
10. Hemmeryckx B, van Wijk A, Reichert A, Kaartinen V, de Jong R, Pattengale PK et al. (2001). Crkl enhances leukemogenesis in BCR/ ABL P190 transgenic mice. Cancer Res 61: 1398-1405.
11. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. (2008). Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
12. Kardinal C, Konkol B, Schulz A, Posern G, Lin H, Adermann K et al. (2000). Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. FASEB J 14: 1529-1538.
13. Kendall J, Liu Q, Bakleh A, Krasnitz A, Nguyen KC, Lakshmi B et al. (2007). Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci USA 104: 16663-16668.
14. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM et al. (2002). The human genome browser at UCSC. Genome Res 12: 996-1006.
15. Kwei KA, Kim YH, Girard L, Kao J, Pacyna-Gengelbach M, Salari K et al. (2008). Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 27: 3635-3640.
16. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X et al. (2008). Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 105: 20380-20385.
17. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE et al. (2007). Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 67: 2081-2088.
18. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
19. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD et al. (2003). c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63: 6272-6281.
20. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
21. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF et al. (1999). Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23: 41-46.
22. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J et al. (2004). Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64: 9027-9034.
23. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS et al. (2006). Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 66: 2116-2128.
24. Sattler M, Salgia R. (1998). Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Leukemia 12: 637-644.
25. Senechal K, Halpern J, Sawyers CL. (1996). The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J Biol Chem 271: 23255-23261.
26. Singer CF, Hudelist G, Lamm W, Mueller R, Handl C, Kubista E et al. (2006). Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol Rep 15: 353-359.
27. Stein D, Wu J, Fuqua SA, Roonprapunt C, Yajnik V, D'Eustachio P et al. (1994). The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J 13: 1331-1340.
28. ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken JW, Heisterkamp N et al. (1994). Cellular interactions of CRKL, and SH2-SH3 adaptor protein. Cancer Res 54: 2563-2567.
29. ten Hoeve J, Morris C, Heisterkamp N, Groffen J. (1993). Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene 8: 2469-2474.
30. Tibshirani R, Wang P. (2008). Spatial smoothing and hot spot detection for CGH data using the fused lasso. Biostatistics 9: 18-29.
31. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y et al. (2005). High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci USA 102: 9625-9630.
32. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R et al. (2007). Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898.
33. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L et al. (2005). Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65: 5561-5570.